The estimated Net Worth of Laurent Fischer is at least 5.86 百万$ dollars as of 15 March 2023. Dr Fischer owns over 41,239 units of Adverum Biotechnologies Inc stock worth over 4,865,751$ and over the last 7 years he sold ADVM stock worth over 76,124$. In addition, he makes 922,916$ as Pres、 CEO、 Interim CMO & Director at Adverum Biotechnologies Inc.
Dr has made over 9 trades of the Adverum Biotechnologies Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 41,239 units of ADVM stock worth 32,166$ on 15 March 2023.
The largest trade he's ever made was selling 41,239 units of Adverum Biotechnologies Inc stock on 15 March 2023 worth over 32,166$. On average, Dr trades about 5,334 units every 41 days since 2017. As of 15 March 2023 he still owns at least 692,141 units of Adverum Biotechnologies Inc stock.
You can see the complete history of Dr Fischer stock trades at the bottom of the page.
Dr. Laurent Fischer is the Pres, CEO, Interim CMO & Director at Adverum Biotechnologies Inc.
As the Pres、 CEO、 Interim CMO & Director of Adverum Biotechnologies Inc, the total compensation of Dr Fischer at Adverum Biotechnologies Inc is 922,916$. There are 3 executives at Adverum Biotechnologies Inc getting paid more, with Leone Patterson having the highest compensation of 2,830,320$.
Dr Fischer is 57, he's been the Pres、 CEO、 Interim CMO & Director of Adverum Biotechnologies Inc since . There are 6 older and 11 younger executives at Adverum Biotechnologies Inc. The oldest executive at Adverum Biotechnologies Inc is Richard Spivey, 69, who is the Independent Director.
Laurent's mailing address filed with the SEC is C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY, CA, 94063.
Over the last 9 years, insiders at Adverum Biotechnologies Inc have traded over 1,591,374$ worth of Adverum Biotechnologies Inc stock and bought 912,973 units worth 4,153,055$ . The most active insiders traders include Patrick Machado、Braden Michael Leonard、Thomas Woiwode. On average, Adverum Biotechnologies Inc executives and independent directors trade stock every 40 days with the average trade being worth of 200,186$. The most recent stock trade was executed by Braden Michael Leonard on 30 July 2024, trading 85,800 units of ADVM stock currently worth 613,470$.
adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.
Adverum Biotechnologies Inc executives and other stock owners filed with the SEC include: